What is the appropriate intravenous amiodarone dosing (bolus and infusion) for a 51 kg male?

Amiodarone Infusion Protocol for a 51 kg Male

Administer the standard FDA-approved fixed-dose regimen: 150 mg IV bolus over 10 minutes, followed by 1 mg/min for 6 hours (360 mg), then 0.5 mg/min for 18 hours (540 mg), with a maximum of 2.2 g in 24 hours—body weight does not alter this dosing. 1, 2

Standard Dosing Protocol (Weight-Independent)

The 2023 ACC/AHA guideline explicitly states that the FDA-approved intravenous amiodarone regimen should be used for all adult patients regardless of body weight. 2 This fixed-dose approach applies equally to your 51 kg patient as it would to a 100 kg patient.

Loading and Maintenance Schedule

• Initial bolus: Give 150 mg diluted in 100 mL D5W over 10 minutes for life-threatening ventricular arrhythmias or hemodynamically unstable tachycardia. 3, 1

• Early maintenance (hours 0–6): Continue at 1 mg/min, delivering approximately 360 mg total during this period. 3, 1

• Late maintenance (hours 6–24): Reduce to 0.5 mg/min for the remaining 18 hours, adding roughly 540 mg. 3, 1

• Total 24-hour exposure: The combined regimen delivers approximately 1,050 mg in the first day; do not exceed 2.2 g within any 24-hour period. 1, 4

Supplemental Boluses for Breakthrough Arrhythmias

• If ventricular tachycardia or fibrillation recurs during the infusion, you may administer up to 6–8 additional 150 mg boluses (each over 10 minutes) within 24 hours. 1

• The 150 mg bolus may be repeated after 10–30 minutes if breakthrough arrhythmias persist. 1

Critical Administration Requirements

Concentration and Line Selection

• Peripheral IV: Keep amiodarone concentration ≤ 2 mg/mL; higher concentrations cause severe phlebitis. 1, 4

• Central line mandatory: For concentrations > 2 mg/mL or infusions expected to last > 1 hour at higher concentrations. 1, 4

• Diluent: Use only 5% dextrose in water (D5W)—normal saline causes drug precipitation. 1, 4

• Equipment: Use a volumetric infusion pump and place an in-line filter in the line. 1

Monitoring Requirements

• Continuous ECG: Monitor for bradycardia (occurs in 4.9% of patients), AV block, QT prolongation, and QRS widening. 1, 2

• Hemodynamic surveillance: Hypotension develops in 16–26% of patients and is rate-dependent; if it occurs during the bolus, slow or pause the infusion. 1, 5

• Electrolyte management: Maintain serum potassium > 4 mmol/L to reduce pro-arrhythmic risk. 1

Absolute Contraindications

• Second- or third-degree AV block without a functioning pacemaker is an absolute contraindication. 1, 2

• Do not administer amiodarone if your patient has high-grade heart block unless a pacemaker is in place. 1

Critical Drug Interactions

• Digoxin: Reduce dose by 50% when starting amiodarone; serum digoxin levels will double. 1

• Warfarin: Decrease dose by 33–50% and monitor INR weekly for 6 weeks; the interaction peaks around week 7. 1

• QT-prolonging drugs: Avoid concomitant use without expert consultation. 1

When to Abandon Pharmacologic Therapy

Immediate synchronized cardioversion should be performed instead of continuing amiodarone if any of the following develop: 1

• Symptomatic hypotension (systolic BP < 90 mm Hg)
• Pulmonary edema
• Ongoing myocardial ischemia or angina
• Hemodynamic instability at any point

Common Pitfalls to Avoid

• Pitfall 1: Do not adjust the dose based on body weight—the 51 kg weight of your patient does not warrant dose reduction. 2

• Pitfall 2: Do not use normal saline or lactated Ringer's as diluent; this causes precipitation and loss of drug efficacy. 1, 4

• Pitfall 3: Do not infuse through a peripheral line at concentrations > 2 mg/mL or for prolonged periods without assessing for phlebitis. 1, 4

• Pitfall 4: Do not forget to reduce digoxin and warfarin doses proactively if the patient is on these medications. 1

• Pitfall 5: If the patient has baseline bradycardia (heart rate < 60 bpm), use amiodarone only if the arrhythmia is immediately life-threatening and no safer alternatives exist. 2

Pharmacokinetic Considerations

• The antiarrhythmic effect typically becomes apparent 20–30 minutes after administration. 1

• Conversion to sinus rhythm most commonly occurs after 6–8 hours and usually requires a cumulative dose ≥ 1 g. 1

• Peak serum concentrations after a 150 mg bolus range from 7–26 mg/L, declining to 10% of peak within 30–45 minutes due to rapid tissue distribution. 4